切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2015, Vol. 04 ›› Issue (01) : 8 -14. doi: 10.3877/cma.j.issn.2095-3224.2015.01.03

所属专题: 指南与规范 文献 指南共识

专家论坛

胃肠道间质瘤诊治指南解读
郁雷1, 梁小波2,()   
  1. 1. 150086 哈尔滨医科大学附属第二医院结直肠肿瘤外科
    2. 山西省肿瘤医院普通外科
  • 收稿日期:2014-11-06 出版日期:2015-02-25
  • 通信作者: 梁小波

Interpretation of guideline for management of gastrointestinal stromal tumour

Lei YU1, Xiao-bo LIANG2,()   

  1. 1. Department of Colorectal Cancer Surgery, The Second Affiliated Hospital, The Colorectal Cancer Institute, Harbin Medical University, Harbin 150086, China
  • Received:2014-11-06 Published:2015-02-25
  • Corresponding author: Xiao-bo LIANG
  • About author:
    Corresponding author: LIANG Xiao-bo, Email:
引用本文:

郁雷, 梁小波. 胃肠道间质瘤诊治指南解读[J/OL]. 中华结直肠疾病电子杂志, 2015, 04(01): 8-14.

Lei YU, Xiao-bo LIANG. Interpretation of guideline for management of gastrointestinal stromal tumour[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2015, 04(01): 8-14.

作为罕见的消化道肿瘤之一,胃肠道间质瘤(gastrointestinal stromal tumors,GISTs)的发病率约为十万分之一。但在消化道的软组织肉瘤中,其发病率位列第一。其可以发生在胃肠道的任何部位,其中以胃和小肠多发,结直肠次之。本解读依据2014年美国国家综合癌症网(National Comprehensive Cancer Network,NCCN)软组织肉瘤治疗指南和2014年欧洲肿瘤学会(European Society of Medical Oncology,ESMO)胃肠道间质瘤治疗指南,从概述、术前诊断方法、手术治疗原则、术后复发风险评估、靶向治疗和随访几个方向对胃肠道间质瘤的诊治进行介绍。意在对消化科医生,尤其是胃肠外科医生的临床工作提供一定帮助。

As the rare tumor in gastrointestinal(GI)tract, the incidence of GISTs is nearly 1/100000.But GISTs are the most common soft tissue sarcoma in the GI tract.It can arise anywhere along the GI tract, but stomach(60%)and small intestine(30%)are the most common sites, followed by colorectal(5% to 6%)primary site(rectum: 4% and colon: 1%~2%). This review consists of overview, diagnosis, principle of surgery, postoperative recurrence risk assessment, targeted therapy and follow up based on 2014 NCCN guidelines version on soft tissue sarcoma and 2014 ESMO guidelines version on GISTs.We hope that it will offer a little help to gastroenterology, especially to the surgeons.

图1 GIST切除可能性初步诊断评估原则流程图
图2 潜在可切除GIST处理原则流程图
图3 不可切除GIST处理原则流程
图4 直径小于2 cm胃肠道间质瘤的处理原则流程图
图5 直径大于2 cm胃肠道间质瘤的处理原则流程图
表1 胃间质瘤术后复发风险评估表
表2 小肠间质瘤术后复发风险评估表
图6 GIST术后伊马替尼治疗策略流程图
图7 伊马替尼治疗中疾病进展后治疗策略流程图
[1]
Nilsson B, Bumming P, Meis-Kindblom JM,et al.Gastrointestinal stromal tumors:the incidence,prevalence clinical course,and prognostication in the pre-imatinibmesylate era-a population based study in western Sweden.Cancer,2005,103:821-829.
[2]
Pappo AS, Janeway KA.Pediatric gastrointestinal stromal tumors.HematolOncolClin North Am,2009,23:15-34.
[3]
Rubin BP, Blanke CD, Demetri GD,et al.Protocol for the examination of specimens from patients with gastrointestinal stromal tumor.Arch Pathol Lab Med,2010,134:165-170.
[4]
Miettinen M, Lasota J.Gastrointestinal stromal tumors:pathology and prognosis at different sites.SeminDiagnPathol,2006,23(2):70-83.
[5]
Demetri GD, von Mehren M, Antonescu CR,et al.NCCN Task Force report:update on the management of patients with gastrointestinal stromal tumors.J NatlComprCancNetw,2010,2:S1-41;S42-4.
[6]
Ohtani H, Maeda K, Noda E,et al.Meta-analysis of laparoscopic and open surgery for gastric gastrointestinal stromal tumor.Anticancer Res,2013,33:5031-5041.
[7]
Gastrointestinal stromal tumor meta-analysis group(MetaGIST).Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors:a meta-analysis of 1640 patients.J ClinOncol,2010,28:1247-1253.
[8]
Demetri GD, van Oosterom AT, Garrett CR,et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib:arandomised controlled trial.Lancet,2006,368:1329-1338.
[9]
Demetri GD, Reichardt P, Kang YK,et al.On behalf of all GRID study investigators.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID):an international,multicentre,randomised,placebo-controlled,phase 3 trial.Lancet,2013,381:295-302.
[10]
Kang YK, Ryu MH, Yoo C,et al.Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib(RIGHT):a randomised,placebo-controlled,phase 3 trial.Lancet Oncol,2013,14:1175-1182.
[11]
ESMO/European Sarcoma Network Working Group.Gastrointestinal stromal tumours:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up.Ann Oncol,2014,3:21-26.
[12]
von Mehren M,Randall RL,National Comprehensive Cancer Network,et al.Soft tissue sarcoma,version2.2014.J NatlComprCancNetw,2014,12(4):473-483.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志(电子版), 2024, 21(11): 1089-1091.
[2] 李友, 唐林峰, 杜伟伟, 刘海亮, 余新水, 沈佳宇, 巨积辉. 皮瓣联合掌长肌腱折叠单排三点式固定治疗指背侧创面伴锤状指畸形的临床效果观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 485-490.
[3] 孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[4] 熊鹰, 林敬莱, 白奇, 郭剑明, 王烁. 肾癌自动化病理诊断:AI离临床还有多远?[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 535-540.
[5] 王秋生. 胆道良性疾病诊疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 779-782.
[6] 刘卓, 张宗明, 张翀, 刘立民, 赵月, 齐晖. 腹腔镜手术治疗高龄急性梗阻性化脓性胆管炎患者的安全性与术式选择[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 795-800.
[7] 陈宗杰, 胡添松. 肝外伤破裂患者治疗后胆漏发生影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 836-840.
[8] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[9] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[10] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[11] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[12] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[13] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[14] 陈慧, 邹祖鹏, 周田田, 张艺丹, 张海萍. 皮肤镜对头皮红斑性皮肤病辅助鉴别诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 692-698.
[15] 胡云鹤, 周玉焯, 付瑞瑛, 于凡, 李爱东. CHS-DRG付费制度下GB1分组住院费用影响因素分析与管理策略探讨[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 568-574.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?